International Immunopharmacology

Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2- breast cancer

ESMO Open

Real-world treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy in the United States

Current Medical Research and Opinion

Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: A systematic review and meta-analysis

Cancer Medicine

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer

American Journal of Clinical Oncology

Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2- advanced or metastatic breast cancer: A systematic review and meta-analysis

Oncology Letters

First-line endocrine therapy for hormone receptor positive and HER 2 negative metastatic breast cancer: A Bayesian network meta analysis

Frontiers in Immunology

Efficacy and safety of different regimens of neoadjuvant therapy in patients with hormone receptor-positive, HER2-negative breast cancer: A network meta-analysis

Translational Oncology

Excavating regulated cell death signatures to predict prognosis, tumor microenvironment and therapeutic response in HR+/HER2- breast cancer

Future Oncology

The NEOLETRIB trial: Neoadjuvant treatment with letrozole and ribociclib in ER-positive, HER2-negative breast cancer

JAMA Surgery

Electronic health record-based nudge intervention and axillary surgery in older women with breast cancer: A nonrandomized controlled trial